Electromed (ELMD) Q4 2026 Earnings Call Transcript

President and Chief Executive Officer - James Cunniff welcomed attendees to Electromed's Q4 2026 earnings call. He highlighted the company's 15th consecutive quarter of revenue and profit growth, attributing it to their direct-to-patient model and increasing recognition of SmartVest within the bronchiectasis community. Q4 brought in $19.4 million in net revenue, a 12% increase from the previous year.

Operating income grew 26% year-over-year to $3.8 million, and earnings per share reached $0.39 per share on a fully diluted basis. Revenue growth was driven by home care and distributor channels. Hospital revenue dropped 29%, but Electromed remains bullish on its potential as a gateway to home care. The company ended the quarter with 64 direct sales representatives and continues to expand its sales force deliberately.

James Cunniff emphasized the significant market opportunity in the underserved bronchiectasis market, noting that 1 million patients in the US have bronchiectasis but only 16% are benefiting from SmartVest therapy. He announced the launch of the "Treat Smart from the start" initiative to help clinicians identify patients who may benefit from changing their airway clearance therapy.

James also mentioned their efforts to raise awareness among healthcare providers through conference presentations, webinars, and national conferences. Additionally, they have published a manuscript in the COPD Foundation Journal, finding that 58% of qualified patients were not prescribed HFCWO therapy despite meeting clinical criteria for insurance coverage.